Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease

WHAT IS KNOWN AND OBJECTIVE: Infliximab is an anti‐tumour necrosis factor agent used in the treatment of inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. While the use of infliximab is well established in the treatment of IBD, there are now four recently...

Descripción completa

Detalles Bibliográficos
Autores principales: Rusch, Caroline, Wood, Marci, Kennedy, Amanda G., Tompkins, Bradley J., Frasca, Joseph D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825869/
https://www.ncbi.nlm.nih.gov/pubmed/36134561
http://dx.doi.org/10.1111/jcpt.13779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825869/
https://www.ncbi.nlm.nih.gov/pubmed/36134561
http://dx.doi.org/10.1111/jcpt.13779

Ejemplares similares